Cost–effectiveness of eszopiclone for the treatment of chronic insomnia

References

• Mack A, Salazar JO. Eszopiclone: a novel cyclopyrrolone with potential benefit in both transient and chronic insomnia. Formulary38, 582–593 (2003).
   Google Scholar
• DiPiro JT. Pharmacotherapy: A Pathophysiologic Approach (5th Edition). McGraw-Hill, NY, USA, 1324–1327 (2002).
   Google Scholar
• Walsh J. Pharmacologic management of insomnia. J. Clin. Psychiatry65(Suppl. 16) 41–45 2004.
   PubMedGoogle Scholar
• Benzodiazepines In: AHFS Drug Information 2004. McEvoy GK (Ed.). American Society of Health-System Pharmacists, Bethesda, MD, USA 23, 2372–2380 (2004).
   Google Scholar
• Zammit G, McNabb L, Caron J, Amato D, Roth T. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr. Med. Res. Opin.20(12), 1979–1991 (2004).
   PubMed Web of Science ®Google Scholar
• Lunesta® tablets. Package Insert. Sepracor Inc, Marlborough, MA, USA (2005).
   Google Scholar
• Smith A, Alder L, Silk J et al. Effect of α subunit on allosteric modulation of ion channel function in stably expressed human recombinant γ-aminobutyric acid A receptors determined using 36 CI ion flux. Mol. Pharmacol.59(5), 1108–1118 (2001).
   PubMed Web of Science ®Google Scholar
• Blasche G, Hempel G, Muller W. Preparative and analytical separation of the zopiclone enantiomers and determination of their affinity to the benzodiazepine receptor binding site. Chirality5, 419–421 (1993).
   PubMedGoogle Scholar
• Caron J, Wessel T, Maier G. Evaluation of a pharmacokinetic interaction between eszopiclone and digoxin. Sleep27(Suppl.) A54 (2004).
   Google Scholar
• Maier G, Koch P, Caron J et al. Dose proportionality and time to steady-state of eszopiclone in healthy adult volunteers following single and multiple dosing. Pharm. Sci.5, M1325 (2003).
   Google Scholar
• Maier G, Rubens, R, Amato D. Pharmacokinetic (PK) and pharmacodynamic (PD) effects of eszopiclone: a comparison of healthly non-elderly and elderly adults. Sleep27(Suppl.) A56 (2004).
   Google Scholar
• Maier G, Roach J, Rubens R. Evaluation of pharmacokinetic and pharmacodynamic interactions between eszopiclone and warfarin. Sleep27 (Suppl.) A56 (2004).
   Google Scholar
• Maier G, Hsu B, Broward M, Russell T, Levasseur L. Evaluation of eszopiclone permeability using the caco-2 in vitro model. Pharm. Sci.5, T2127 (2003).
   Google Scholar
• Leese P, Maier G, Vaickus L, Akylbekova E. Eszopiclone: pharmacokinetic and pharmacodynamic effects of a novel sedative hypnotic after daytime administration in healthy subjects. In: Program and abstracts of the Association of Profession Sleep Societies Annual Meeting. Seattle, WA. 8–13 June, 2002 (Abstract 45).
   Google Scholar
• Krystal AD, Walsh JK, Laska E et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep26(7), 793–799 (2003).
   PubMed Web of Science ®Google Scholar
• McCall WV, Erman M, Krystal AD et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Curr. Med. Res. Opin.22(9), 1633–1642 (2006).
   PubMed Web of Science ®Google Scholar
• Roth T, Walsh JK, Krystal A et al. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med.6, 487–495 (2005).
   PubMed Web of Science ®Google Scholar
• Morin CM, Culbert JP, Schwartz SM. Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy. Am. J. Psychiatry151(8), 1172–1180 (1994).
   PubMed Web of Science ®Google Scholar
• Scharf M, Erman M, Rosenberg R et al. A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep28(6), 720–727 (2005).
   PubMed Web of Science ®Google Scholar
• Ozminkowski R, Lenhart G. Forecasting the impact of adding a new drug on formulary using medical claims data and clinical literature. A case study of insomnia treatment. Value Health8, 323 [Abstract] (2005).
   Google Scholar
• Drug Topics Red Book 2004. Thomson PDR, NJ, USA (2004).
   Google Scholar
• Melton ST, Wood JM. Eszopiclone for insomnia. Ann. Pharmacotherapy39, 1659–1666 (2005).
   PubMed Web of Science ®Google Scholar
• Soares CN, Joffe H, Rubens R et al. Eszopiclone in patients with insomnia during perimenopause and early menopause. Obstet. Gynecol.108(6), 1402–1410 (2006).
   PubMed Web of Science ®Google Scholar
• Fava M, McCall V, Krystal A et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol. Psychiatry59, 1052–1060 (2006).
   PubMed Web of Science ®Google Scholar
• Krystal A, Walsh J, RothT, Rubens R, Wessel T. Efficacy and safety of six months of nightly eszopiclone in patients with primary insomnia. Ann. Neurol.58(Suppl. 9) S67[Abstract] (2005).
   Google Scholar
• Pollack M, Kinrys G, Krystal A et al. Evaluation of eszopiclone and escitalopram oxalate co-therapy in patients with generalized anxiety disorder and insomnia. Neuropsychopharmacology31(Suppl. 1), [Abstract] (2006).
   Google Scholar
• Schnitzer T, Rubens R, Wessel Tet al. The effect of eszopiclone 3 mg compared with placebo in patients with rheumatoid arthritis and co-existing insomnia. Sleep29 A238 [Abstract] (2006).
   Google Scholar
• NIH state of the science conference statement on manifestations and management of chronic insomnia in adults statement. manifestations and management of chronic insomnia in adults June 13–15, 2005. J. Clin. Sleep Med.1(4), 412–421 (2005).
   PubMedGoogle Scholar
• Martin SA, Aikens JE, Chervin Rd. Toward cost–effectiveness analysis in the diagnosis and treatment of insomnia. Sleep Med. Rev.8, 63–72 (2004).
   PubMed Web of Science ®Google Scholar